The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Association of sarcopenia with mortality and end‐stage renal disease in those with chronic kidney disease: a UK Biobank study
Open accessAbstract
Background: Sarcopenia, a degenerative and generalized skeletal muscle disorder involving the loss of muscle function and mass, is an under‐recognized problem in clinical practice, particularly in chronic kidney disease (CKD). We aimed to investigate the prevalence of sarcopenia in individuals with CKD, its risk factors, and its association with all‐cause mortality and progression to end‐stage renal disease (ESRD). Methods: UK Biobank participants were grouped according to the presence of CKD (defined as an estimated glomerular filtration rate <60 mL/min/1.73 m 2 ) and as having probable (low handgrip strength), confirmed (plus low muscle mass), and severe sarcopenia (plus poor physical performance) based on the 2019 European Working Group of Sarcopenia in Older People and Foundation for the National Institutes of Health criteria. Risk factors were explored using logistic regression analysis. Survival models were applied to estimate risk of mortality and ESRD. Results: A total of 428 320 participants, of which 8767 individuals with CKD (46% male, aged 62.8 (standard deviation 6.8) years, median estimated glomerular filtration rate 54.5 (interquartile range 49.0–57.7) mL/min/1.72 m 2 ) were included. Probable sarcopenia was present in 9.7% of individuals with CKD compared with 5.0% in those without ( P < 0.001). Sarcopenia was associated with being older; inflammation; poorer renal function; and lower serum albumin, total testosterone, and haemoglobin. The largest risk factors for sarcopenia were having three or more comorbidities (odds ratio: 2.30; 95% confidence interval: 1.62 to 3.29; P < 0.001) and physical inactivity: participants in the highest quartile of weekly activity were 43% less likely to have sarcopenia compared to the lowest quartile (odds ratio: 0.57; 0.42 to 0.76; P < 0.001). Participants with CKD and sarcopenia had a 33% (7% to 66%; P = 0.011) higher hazard of mortality compared with individuals without. Sarcopenic CKD individuals had a 10 year survival probability of 0.85 (0.82 to 0.88) compared with 0.89 (0.88 to 0.30) in those without sarcopenia, an absolute difference of 4%. Those with sarcopenia were twice as likely to develop ESRD (hazard ratio: 1.98; 1.45 to 2.70; P < 0.001). Conclusions: Participants with reduced kidney function are at an increased risk of premature mortality. The presence of sarcopenia increases the risk of mortality and ESRD. Appropriate measurement of sarcopenia should be used to identify at‐risk individuals. Interventions such as physical activity should be encouraged to mitigate sarcopenia.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Sarcopenia: revised European consensus on definition and diagnosis
Cruz-Jentoft, A. J., Bahat, G., Bauer, J., Boirie, Y., Bruyère, O., Cederholm, T., Cooper, C., Landi, F., Rolland, Y., Sayer, A. A., et al. (2019) · Age and Ageing · doi:10.1093/ageing/afy169 · Cited by 13,818
Fry, A., Littlejohns, T. J., Sudlow, C., Doherty, N., Adamska, L., Sprosen, T., Collins, R., & Allen, N. E. (2017) · American Journal of Epidemiology · doi:10.1093/aje/kwx246 · Cited by 3,979
Sarcopenia: revised European consensus on definition and diagnosis
Cruz-Jentoft, A. J., Bahat, G., Bauer, J., Boirie, Y., Bruyère, O., Cederholm, T., Cooper, C., Landi, F., Rolland, Y., Sayer, A. A., et al. (2019) · Age and Ageing · doi:10.1093/ageing/afz046 · Cited by 3,803
Studenski, S. A., Peters, K. W., Alley, D. E., Cawthon, P. M., McLean, R. R., Harris, T. B., Ferrucci, L., Guralnik, J. M., Fragala, M. S., Kenny, A. M., et al. (2014) · The Journals of Gerontology: Series A · doi:10.1093/gerona/glu010 · Cited by 2,545
The healthcare costs of sarcopenia in the United States
Janssen, I., Shepard, D. S., Katzmarzyk, P. T., & Roubenoff, R. (2004) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.2004.52014.x · Cited by 1,546
Visser, M., Pahor, M., Taaffe, D. R., Goodpaster, B. H., Simonsick, E. M., Newman, A. B., Nevitt, M., & Harris, T. B. (2002) · The Journals of Gerontology Series A: Biological Sciences and Medical Sciences · doi:10.1093/gerona/57.5.m326 · Cited by 1,294
Dent, E., Morley, J. E., Cruz-Jentoft, A. J., Arai, H., Kritchevsky, S. B., Guralnik, J., Bauer, J. M., Pahor, M., Clark, B. C., Cesari, M., et al. (2018) · The Journal of nutrition, health and aging · doi:10.1007/s12603-018-1139-9 · Cited by 1,130 · cited 1×
“particularly the use of resistance exercise, remains one of the key modifiable risk factors of sarcopenia and is generally considered the ‘primary’ form of treatment.(1,3)”
BackgroundCelis-Morales, C. A., Welsh, P., Lyall, D. M., Steell, L., Petermann, F., Anderson, J., Iliodromiti, S., Sillars, A., Graham, N., Mackay, D. F., et al. (2018) · BMJ · doi:10.1136/bmj.k1651 · Cited by 772
Batty, G. D., Gale, C. R., Kivimäki, M., Deary, I. J., & Bell, S. (2020) · BMJ · doi:10.1136/bmj.m131 · Cited by 635 · cited 1×
“a major concern in our analysis, as also empirically demonstrated.(61) The differences in risk factors (e.”
BackgroundUK Biobank: Current status and what it means for epidemiology
Allen, N., Sudlow, C., Downey, P., Peakman, T., Danesh, J., Elliott, P., Gallacher, J., Green, J., Matthews, P., Pell, J., et al. (2012) · Health Policy and Technology · doi:10.1016/j.hlpt.2012.07.003 · Cited by 521
The impact of obesity on skeletal muscle strength and structure through adolescence to old age
Tomlinson, D. J., Erskine, R. M., Morse, C. I., Winwood, K., & Onambélé-Pearson, G. (2016) · Biogerontology · doi:10.1007/s10522-015-9626-4 · Cited by 496 · cited 1×
“forearm muscles as required for HGS), these individuals appear weaker.(60) Indeed, we found participants with CKD exhibited lower HGS compared with the non-CKD group.”
BackgroundPhysical activity, multimorbidity, and life expectancy: a UK Biobank longitudinal study
Chudasama, Y. V., Khunti, K. K., Zaccardi, F., Rowlands, A. V., Yates, T., Gillies, C. L., Davies, M. J., & Dhalwani, N. N. (2019) · BMC Medicine · doi:10.1186/s12916-019-1339-0 · Cited by 353
Self-citationHerrington, W. G., Smith, M., Bankhead, C., Matsushita, K., Stevens, S., Holt, T., Hobbs, F. D. R., Coresh, J., & Woodward, M. (2017) · PLOS ONE · doi:10.1371/journal.pone.0173515 · Cited by 141 · cited 2×
“This algorithm has previously been used to successfully identify those with ESRD in the UK Biobank.31 Participants identified with existing ESRD at baseline visit (either detected by hospital admission records or self-report) (‘prevalent ESRD’) were excluded from the analysis.”
MethodShin, M. J., Jeon, Y. K., & Kim, I. J. (2018) · The World Journal of Men's Health · doi:10.5534/wjmh.180001 · Cited by 134
Research works printed but not linked: 49
- 10.1016/S0140-6736(19)31138-9 · DOI · Paper page
- 10.1111/jgs.16575 · DOI
- 10.1371/journal.pone.0169548 · DOI · Paper page
- 10.1016/j.clnu.2018.09.026 · DOI
- 10.1093/gerona/glu013 · DOI · Paper page
- 10.22540/JFSF-04-071 · DOI
- 10.1097/MNH.0000000000000318 · DOI · Paper page
- 10.1053/j.ajkd.2017.01.051 · DOI · Paper page
- 10.1093/ndt/gft070 · DOI · Paper page
- 10.1371/journal.pone.0176230 · DOI · Paper page
- 10.5812/numonthly.37443 · DOI
- 10.3109/0886022X.2015.1132173 · DOI · Paper page
- 10.1111/nep.13678 · DOI
- 10.2215/CJN.10261013 · DOI · Paper page
- 10.1016/j.clnu.2013.04.002 · DOI · Paper page
- 10.1186/s12882-019-1271-8 · DOI
- 10.3904/kjim.2017.083 · DOI
- 10.1016/j.ekir.2016.10.008 · DOI
- 10.1016/j.nut.2020.110815 · DOI
- 10.1681/ASN.2012070702 · DOI · Paper page
- 10.3390/nu11061378 · DOI
- 10.1111/j.1523-1755.2005.00365.x · DOI · Paper page
- 10.1002/jcsm.12503 · DOI · Paper page
- 10.1016/j.jamda.2014.11.004 · DOI
- 10.1017/jns.2017.66 · DOI · Paper page
- 10.1002/sim.1203 · DOI · Paper page
- 10.1093/ndt/gfw466 · DOI
- 10.1093/ndt/gfv133 · DOI · Paper page
- 10.1007/s41999-020-00310-5 · DOI
- 10.1007/s00223-013-9830-7 · DOI · Paper page
- 10.1093/ageing/afaa077 · doi:10.1093/ageing/afaa077
- 10.1093/ajcn/81.1.79 · DOI · Paper page
- 10.1093/ndt/17.7.1266 · DOI · Paper page
- 10.1093/ndt/gfq487 · doi:10.1093/ndt/gfq487
- 10.1186/s12882-020-01831-8 · DOI
- 10.1093/ndt/gfr013 · DOI
- 10.1177/2047487319885041 · DOI
- 10.1096/fj.201901936RR · DOI
- 10.1002/ajhb.20956 · DOI · Paper page
- 10.1159/000101827 · DOI · Paper page
- 10.1016/j.metabol.2016.07.003 · DOI
- Wilkinson TJ, 2017, Commentary: Renal function estimation and Cockcroft‐Gault formulas for predicting cardiovascular mortality in population‐based, cardiovascular risk, heart failure and post‐myocardial infarction cohorts: the Heart ‘OMics’ in AGEing (HOMAGE) and the high‐risk myocardial infarction database initiatives, Front Med (Lausanne), 4, 77, 10.3389/fmed.2017.00077 · doi:10.3389/fmed.2017.00077
- 10.1016/j.jamda.2018.06.011 · DOI
- 10.1016/j.maturitas.2016.11.006 · DOI · Paper page
- 10.1016/S0272-6386(03)00654-1 · DOI · Paper page
- 10.1002/jcsm.12218 · DOI
- 10.1093/ndt/gfz235 · DOI · Paper page
- 10.2147/CIA.S132940 · DOI · Paper page
- 10.1002/jcsm.12501 · DOI · Paper page
Metadata
- Authors
- Wilkinson, T. J., Miksza, J., Yates, T., Lightfoot, C. J., Baker, L. A., Watson, E. L., Zaccardi, F., & Smith, A. C.
- Venue
- Journal of Cachexia, Sarcopenia and Muscle
- Publisher
- Wiley
- Published
- 2021-05-05
- Volume
- 12
- Issue
- 3
- Pages
- 586-598
- ISSN
- 2190-5991 (ISSN-L)
- 2190-6009
- OpenAlex
- W3158761451
- Cited by
- 227
- References
- 14
- FWCI
- 16.19
- Type
- journal article
- Language
- en
- Open access
- gold
- Funders
- British Heart Foundation
- Northwest Regional Development Agency
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.